Literature DB >> 15079005

Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1.

E L Logigian1, R T Moxley, C L Blood, C A Barbieri, W B Martens, A W Wiegner, C A Thornton, R T Moxley.   

Abstract

OBJECTIVE: To quantitate hand muscle myotonia and to assess the relationship between CTG repeat length and myotonia in myotonic dystrophy type 1 (DM1).
METHODS: First dorsal interosseous twitch and tetanic contractions evoked by single and 10-Hz ulnar nerve stimulation were recorded with a force transducer in 15 patients with genetically confirmed DM1 and 15 control subjects. An automated computer program analyzed three single and three tetanic recordings per subject on 2 successive days by placing cursors along the declining (relaxation) phase of the force recordings at 90, 50, and 5% of peak force (PF) and calculating relaxation times (RT) between these points.
RESULTS: Tetanic and twitch RT was longer and PF lower in patients than subjects. RT (90 to 5%) was above the normal mean + 2.5 SD in 13 tetanic (87%) and 11 (73%) twitch patient recordings. In DM1, prolongation of RT was due mainly to delay in the terminal (50 to 5%), rather than the initial (90 to 50%) phase of relaxation, and was much greater in tetanic than single-twitch recordings. Mean test-retest variability was 19% for tetanic RT and 16% for tetanic PF. In DM1, both tetanic and twitch RT were positively correlated with leukocyte CTG repeat length.
CONCLUSIONS: In DM1, myotonia of intrinsic hand muscles can be quantitated reliably by automated analysis of tetanic and twitch RT, targeting, in particular, the terminal phase of muscle relaxation after tetanic stimulation. Severity of hand muscle myotonia depends on CTG repeat length consistent with a "triplet repeat dosage" effect on chloride channel mRNA splicing and function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15079005     DOI: 10.1212/01.wnl.0000118206.49652.a3

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes.

Authors:  Gayle Overend; Cécilia Légaré; Jean Mathieu; Luigi Bouchard; Cynthia Gagnon; Darren G Monckton
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

2.  Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1.

Authors:  Chad R Heatwole; Katy J Eichinger; Deborah I Friedman; James E Hilbert; Carlayne E Jackson; Eric L Logigian; William B Martens; Michael P McDermott; Shree K Pandya; Christine Quinn; Alexis M Smirnow; Charles A Thornton; Richard T Moxley
Journal:  Arch Neurol       Date:  2010-09-13

3.  An Integrative Analysis of DNA Methylation Pattern in Myotonic Dystrophy Type 1 Samples Reveals a Distinct DNA Methylation Profile between Tissues and a Novel Muscle-Associated Epigenetic Dysregulation.

Authors:  Emma Koehorst; Renato Odria; Júlia Capó; Judit Núñez-Manchón; Andrea Arbex; Miriam Almendrote; Ian Linares-Pardo; Daniel Natera-de Benito; Verónica Saez; Andrés Nascimento; Carlos Ortez; Miguel Ángel Rubio; Jordi Díaz-Manera; Jorge Alonso-Pérez; Giuseppe Lucente; Agustín Rodriguez-Palmero; Alba Ramos-Fransi; Alicia Martínez-Piñeiro; Gisela Nogales-Gadea; Mònica Suelves
Journal:  Biomedicines       Date:  2022-06-10

4.  Polypoidal choroidal vasculopathy in a patient with DMPK-associated myotonic dystrophy.

Authors:  Yuka Iida; Takaaki Hayashi; Teruaki Tokuhisa; Kei Mizobuchi; Shusaku Omoto; Tadashi Nakano
Journal:  Doc Ophthalmol       Date:  2022-03-13       Impact factor: 1.854

5.  Evoked myotonia can be "dialed-up" by increasing stimulus train length in myotonic dystrophy type 1.

Authors:  Eric L Logigian; Paul Twydell; Nuran Dilek; William B Martens; Chris Quinn; Allen W Wiegner; Chad R Heatwole; Charles A Thornton; Richard T Moxley
Journal:  Muscle Nerve       Date:  2010-02       Impact factor: 3.217

Review 6.  Clinical evaluation of membrane excitability in muscle channel disorders: potential applications in clinical trials.

Authors:  James C Cleland; Eric L Logigian
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

7.  A quantitative measure of handgrip myotonia in non-dystrophic myotonia.

Authors:  Jeffrey M Statland; Brian N Bundy; Yunxia Wang; Jaya R Trivedi; Dipa Raja Rayan; Laura Herbelin; Merideth Donlan; Rhonda McLin; Katy J Eichinger; Karen Findlater; Liz Dewar; Shree Pandya; William B Martens; Shannon L Venance; Emma Matthews; Anthony A Amato; Michael G Hanna; Robert C Griggs; Richard J Barohn
Journal:  Muscle Nerve       Date:  2012-10       Impact factor: 3.217

Review 8.  Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.

Authors:  Samantha LoRusso; Benjamin Weiner; W David Arnold
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 9.  Drug treatment for myotonia.

Authors:  J Trip; G Drost; B G M van Engelen; C G Faber
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

10.  Cell-free cloning of highly expanded CTG repeats by amplification of dimerized expanded repeats.

Authors:  Robert J Osborne; Charles A Thornton
Journal:  Nucleic Acids Res       Date:  2008-02-07       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.